Key result
Postprocedural treatment with ASA, ticlopidine, and abciximab was associated with a lower rate of subacute stent thrombosis compared to ASA and heparin (2% vs 17%, P<0.05).
Why the study?
Does postprocedural treatment with ASA and ticlopidine plus abciximab reduce subacute stent thrombosis compared to ASA and heparin in patients with acute myocardial infarction undergoing Micro stent implantation?
Cohort (n=104)
Does postprocedural treatment with ASA and ticlopidine plus abciximab reduce subacute stent thrombosis compared to ASA and heparin in patients with acute myocardial infarction undergoing Micro stent implantation?
Absolute Event Rate: 2% vs 17%
p-value: p=<0.05
Postprocedural treatment with ASA and ticlopidine (plus abciximab if indicated) significantly reduces the risk of subacute stent thrombosis compared to ASA and heparin after Micro stent implantation in acute myocardial infarction.
May support triple antithrombotic regimen post-AMI stenting; leaves open randomized confirmation before practice change.
The 4-week outcome following Micro stent implantation for acute myocardial infarction was assessed with the use of two different antithrombotic regimens. The patients were postprocedurally treated with acetyl salicylic acid (ASA) and heparin for 24–48 h (Group I; n = 52), or ASA and ticlopidine plus abciximab if indicated (Group II; n = 52). Stent implantation was successful in 49 patients (94%) of group I and in 46 patients (89%) of group II (NS). Subacute stent thrombosis occurred in nine patients (17%) of group I and in 1 patient (2%) of group II (P < 0.05). There were no significant differences in the rates of mortality, coronary bypass operation, or vascular complications. Micro stent implantation in acute myocardial infarction is highly effective and associated with a low risk for subacute stent thrombosis if the patients are postprocedurally treated with ASA and ticlopidine plus abciximab if indicated. Cathet. Cardiovasc. Diagn. 44:131–137, 1998.
No takes yet. Share an insight, caveat, or question.
Oemrawsingh et al. (1998) conducted a cohort in Acute myocardial infarction (n=104). ASA and ticlopidine plus abciximab if indicated vs. ASA and heparin for 24-48 h was evaluated on Subacute stent thrombosis (p=<0.05). Postprocedural treatment with ASA, ticlopidine, and abciximab was associated with a lower rate of subacute stent thrombosis compared to ASA and heparin (2% vs 17%, P<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: